https://doi.org/10.4081/gc.2022.10150
Role of interleukin-4 and their antagonistic effect in asthma
Submitted: 23 September 2021
Accepted: 14 March 2022
Published: 18 March 2022
Accepted: 14 March 2022
Abstract Views: 2179
PDF: 249
HTML: 349
HTML: 349
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Asthma is a chronic inflammatory disease of the lower airways, characterize by wheezing cough, chest tightness along with inflammation of airway and shortness of breath. Allergens like environmental substance are predispose asthmatics patients to allergy. Mast cells produced interleukin (IL)- 4 which either activate signal transducer and activator of transcription 6 (STAT-6) pathway that involved in differentiation of na ve T-cells to TH2 or activation of TH2 cells indirectly. The aim of the current context is to present role of IL-4 in asthma and effect as antagonist. IL-4 results in increased mucus production and involve in IgE synthesis from B cells. IL4 facilitate chemotaxis and aid in displaying of VCAM-1 which attract eosinophil basophils monocytes T-lymphocytes to blood vessel. IL4 inhibit apoptosis either by preventing decrease in BCL-2 level or binding of FasL to Fas (cd32) receptor which result in acute allergic response. Elevated level of IL-4 has greatly adverse impact on asthmatic patients so by decreasing the level of IL-4 will greatly reduce asthma phenotype.
Manni ML, Alcorn JF. The enigmatic role of IL-22 in asthma. Expert Rev Respir Med 2016;10:619-23.
DOI: https://doi.org/10.1080/17476348.2016.1174580
Selgrade MK, Lemanske Jr RF, Gilmour MI, et al. Induction of asthma and the environment: what we know and need to know. Environ Health Perspect 2006;114:615-9.
DOI: https://doi.org/10.1289/ehp.8376
Kudo M, Ishigatsubo Y, Aoki I. Pathology of asthma. Front Microbiol 2013;4:263.
DOI: https://doi.org/10.3389/fmicb.2013.00263
Grammatikos AP. The genetic and environmental basis of atopic diseases. Annals Med 2008;40:482-95.
DOI: https://doi.org/10.1080/07853890802082096
Khan AA, Tanzil S, Jamali T, et al. Burden of asthma among children in a developing megacity: childhood asthma study, Pakistan. J Asthma 2014;51:891-9.
DOI: https://doi.org/10.3109/02770903.2014.930882
O'Byrne PM, Inman MD, Adelroth E. Reassessing the Th2 cytokine basis of asthma. Trends Pharmacol Sci 2004;25:244-8.
DOI: https://doi.org/10.1016/j.tips.2004.03.008
Ashraf MI, Shahzad M, Shabbir A. Oxyresveratrol ameliorates allergic airway inflammation via attenuation of IL-4, IL-5, and IL-13 expression levels. Cytokine 2015;76:375-81.
DOI: https://doi.org/10.1016/j.cyto.2015.09.013
Pawankar R, Okuda M, Yssel H, et al. Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J Clin Investig 1997;99:1492-9.
DOI: https://doi.org/10.1172/JCI119311
Oh C, Geba G, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev 2010;19:46-54.
DOI: https://doi.org/10.1183/09059180.00007609
Steinke JW. Anti-interleukin-4 therapy. Immunol Allergy Clin 2004;24:599-614.
DOI: https://doi.org/10.1016/j.iac.2004.06.008
Kumar V, Abbas AK, Aster JC. Robbins basic pathology. E-book: Elsevier Health Sciences; 2017.
Gao H, Ying S, Dai Y. Pathological roles of neutrophil-mediated inflammation in asthma and its potential for therapy as a target. J Immunol Res 2017;2017.
DOI: https://doi.org/10.1155/2017/3743048
Steinke JW, Borish L. Th2 cytokines and asthma - Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respirat Res 2001;2:66.
DOI: https://doi.org/10.1186/rr40
Vella A, Teague TK, Ihle J, et al. Interleukin 4 (IL-4) or IL-7 prevents the death of resting T cells: stat6 is probably not required for the effect of IL-4. J Exper Med 1997;186:325-30.
DOI: https://doi.org/10.1084/jem.186.2.325
Shi H-Z, Deng J-M, Xu H, et al. Effect of inhaled interleukin-4 on airway hyperreactivity in asthmatics. Am J Respir Crit Care Med 1998;157:1818-21.
DOI: https://doi.org/10.1164/ajrccm.157.6.9710023
McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine 2015;75:38-50.
DOI: https://doi.org/10.1016/j.cyto.2015.05.023
Huang S-K, Xiao H-Q, Kleine-Tebbe J, et al. IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol 1995;155:2688-94.
Graber P, Gretener D, Herren S, et al. The distribution of IL‐13 receptor α1 expression on B cells, T cells and monocytes and its regulation by IL‐13 and IL‐4. Eur J Immunol 1998;28:4286-98.
DOI: https://doi.org/10.1002/(SICI)1521-4141(199812)28:12<4286::AID-IMMU4286>3.0.CO;2-H
Weng S-Y, Wang X, Vijayan S, et al. IL-4 receptor alpha signaling through macrophages differentially regulates liver fibrosis progression and reversal. EBioMed 2018;29:92-103.
DOI: https://doi.org/10.1016/j.ebiom.2018.01.028
Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001;107:963-70.
DOI: https://doi.org/10.1067/mai.2001.115624
Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007;370:1422-31.
DOI: https://doi.org/10.1016/S0140-6736(07)61600-6
Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma: a phase I/II randomized, placebo-controlled trial. Am J Respirat Critical Care Med 1999;160:1816-23.
DOI: https://doi.org/10.1164/ajrccm.160.6.9808146
Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet 2015;386:1086-96.
DOI: https://doi.org/10.1016/S0140-6736(15)00157-9
How to Cite
Khan, M. U. A., Akhtar, T., Khan, M. Y. A., Faheem, M. A., Salahuddin, Z. ., & Muhammad, N. (2022). Role of interleukin-4 and their antagonistic effect in asthma. Geriatric Care, 8(1). https://doi.org/10.4081/gc.2022.10150
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.